Education
About Us
Working with TipRanks
Follow Us
Aurobindo Pharma Ltd (IN:AUROPHARMA)
:AUROPHARMA
RESEARCH TOOLSreports
Total Valuation
Aurobindo Pharma Ltd has a market cap or net worth of ₹669.61B. The enterprise value is ₹669.36B.
Market Cap₹669.61B
Enterprise Value₹669.36B
Share Statistics
Aurobindo Pharma Ltd has 580,801,640 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding580,801,640
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Aurobindo Pharma Ltd’s return on equity (ROE) is 0.11 and return on invested capital (ROIC) is 23.53%.
Return on Equity (ROE)0.11
Return on Assets (ROA)0.07
Return on Invested Capital (ROIC)23.53%
Return on Capital Employed (ROCE)0.41
Revenue Per Employee12.19M
Profits Per Employee1.34M
Employee Count26,015
Asset Turnover0.64
Inventory Turnover1.24
Valuation Ratios
The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio19.3
PS Ratio0.00
PB Ratio2.05
Price to Fair Value2.02
Price to FCF0.00
Price to Operating Cash Flow0.00
PEG Ratio229.34
Income Statement
In the last 12 months, Aurobindo Pharma Ltd had revenue of 317.24B and earned 34.86B in profits. Earnings per share was 59.81.
Revenue317.24B
Gross Profit186.97B
Operating Income142.22B
Pretax Income50.66B
Net Income34.86B
EBITDA66.05B
Earnings Per Share (EPS)59.81
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Aurobindo Pharma Ltd pays an annual dividend of ₹1.5, resulting in a dividend yield of 0.39%
Dividend Per Share₹1.5
Dividend Yield0.39%
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.00
52-Week Price Change-14.40%
50-Day Moving Average1.16K
200-Day Moving Average1.22K
Relative Strength Index (RSI)48.04
Average Volume (3m)32.15K
Important Dates
Aurobindo Pharma Ltd upcoming earnings date is Aug 7, 2025, TBA (Confirmed).
Last Earnings DateMay 26, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend DateFeb 20, 2024
Financial Position
Aurobindo Pharma Ltd as a current ratio of 1.85, with Debt / Equity ratio of 25.30%
Current Ratio1.85
Quick Ratio1.13
Debt to Market Cap0.12
Net Debt to EBITDA<0.01
Interest Coverage Ratio31.10
Taxes
In the past 12 months, Aurobindo Pharma Ltd has paid 15.83B in taxes.
Income Tax15.83B
Effective Tax Rate0.31
Enterprise Valuation
Aurobindo Pharma Ltd EV to EBITDA ratio is 10.01, with an EV/FCF ratio of 33.79.
EV to Sales2.08
EV to EBITDA10.01
EV to Free Cash Flow33.79
EV to Operating Cash Flow16.85
Balance Sheet
Aurobindo Pharma Ltd has ₹82.36B in cash and marketable securities with ₹82.63B in debt, giving a net cash position of ₹273.70M billion.
Cash & Marketable Securities₹82.36B
Total Debt₹82.63B
Net Cash₹273.70M
Net Cash Per Share₹0.47
Tangible Book Value Per Share₹487.42
Margins
Gross margin is 58.63%, with operating margin of 44.83%, and net profit margin of 10.99%.
Gross Margin58.63%
Operating Margin44.83%
Pretax Margin15.97%
Net Profit Margin10.99%
EBITDA Margin20.82%
EBIT Margin15.62%
Analyst Forecast
The average price target for Aurobindo Pharma Ltd is ₹1,430.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target₹1,430.00
Price Target Upside21.25% Upside
Analyst ConsensusModerate Buy
Analyst Count4
Revenue Growth Forecast9.39%
EPS Growth Forecast10.59%